(Q33415437)

26 July 2017

title

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors (English)

1 reference

26 July 2017

Robert Bristow

11

0 references

author name string

Monica Mita

1

1 reference

26 July 2017

Michael Gordon

2

1 reference

26 July 2017

Lee Rosen

3

1 reference

26 July 2017

Nirmal Kapoor

4

1 reference

26 July 2017

Gavin Choy

5

1 reference

26 July 2017

Sanjeev Redkar

6

1 reference

26 July 2017

Pietro Taverna

7

1 reference

26 July 2017

Aram Oganesian

8

1 reference

26 July 2017

Amarpal Sahai

9

1 reference

26 July 2017

Mohammad Azab

10

1 reference

26 July 2017

Anthony W Tolcher

12

1 reference

26 July 2017

publication date

22 May 2014

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

74

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

195-204

1 reference

Resistance to chemotherapy: new treatments and novel insights into an old problem

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

Microscopic imaging of DNA repair foci in irradiated normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2481-1

10.1007/S00280-014-2481-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1020916756

0 references

1 reference